This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free daily Manufacturing Dive newsletter. Dive Brief: AbbVie announced it will spend $380 million to build two new U.S. facilities at its existing campus in North Chicago, Illinois that will integrate advanced manufacturing technologies with artificial intelligence to produce next-generation neuroscience and obesity drugs. Construction will begin in spring of 2026, with the plants scheduled ...

AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its Illinois campus, expanding its domestic production capacity for its... ...

Financial Statement Release - Orion will publish its Financial Statement Release for 2025 on 12 February 2026 at approximately 12.00 noon EET [1] - The release and related presentation material will be available on the company's website after publishing [1] Webcast and Conference Call - A webcast and conference call for analysts, investors, and media representatives will be held on 12 February 2026 at 14.00 EET [2] - A link to the live webcast will be available on Orion's website, and a recording will be accessible later the same day [2] - Registration is required to join the conference call, with details provided through a specific link [2][3] Company Overview - Orion is a Nordic pharmaceutical company with over a hundred years of experience, focusing on developing, manufacturing, and marketing human and veterinary pharmaceuticals [5] - The company reported net sales of EUR 1,542 million in 2024 and employs approximately 3,700 professionals globally [5] - Orion's core therapy areas in pharmaceutical R&D include oncology and pain management, with proprietary products aimed at treating cancer, neurological diseases, and respiratory diseases [5]

Core Viewpoint - EUROAPI's main shareholders, Sanofi and EPIC Bpifrance, have agreed to extend their lock-up period until December 18, 2026, enhancing the stability of EUROAPI's shareholding structure during the execution of its FOCUS-27 plan [1] Business Update - The execution of the FOCUS-27 plan is progressing well, with ongoing improvements in cost efficiency across the organization [1] - EUROAPI anticipates a mid-single digit decrease in Full Year 2025 Net Sales on a comparable basis, a revision from the previously communicated low-single digit decline [5] - The Core EBITDA margin objective for Full Year 2025 remains within the 7% to 9% range due to effective cost reduction measures [5] - A further update will be provided on March 3, 2026, alongside the Full Year 2025 Results [1][5] Company Overview - EUROAPI focuses on reinventing active ingredient solutions to meet global customer and patient needs, with approximately 200 products in its portfolio [2] - The company operates five manufacturing sites in Europe and serves customers in over 80 countries [3] - EUROAPI is listed on Euronext Paris under the ticker EAPI [3]

Company Overview - Teva Pharmaceutical Industries Limited is a leading global pharmaceutical company with a strong presence in both the generic and specialty drug markets, focusing on delivering accessible medicines across various therapeutic areas [1] - The company generates revenue through the development, manufacturing, and global distribution of prescription drugs and active pharmaceutical ingredients, utilizing both branded and generic product lines [2] Financial Performance - As of December 05, 2025, Teva's shares were priced at $28.46, reflecting a 63.5% increase over the past year, significantly outperforming the S&P 500 by 49.6 percentage points [2] - Over the last five years, Teva's shares have appreciated by 157%, resulting in a compound annual growth rate (CAGR) of 20.7%, which surpasses the S&P 500's total return of 99% and a CAGR of 14.8% during the same period [8] Institutional Investment - Glenview Capital Management reported a net increase of 868,457 shares in Teva during the third quarter, with the position's value rising to $337.19 million as of September 30, 2025, due to price appreciation and additional share accumulation [3][4] - Glenview's recent acquisition of approximately $72 million worth of Teva stock during the third quarter indicates a strong conviction in the company, making Teva the 4th-largest position in Glenview's portfolio, totaling 16.7 million shares valued at around $337 million [7][8]

Manufacturing Expansion & Investment - Eli Lilly is investing $5 billion in a new US manufacturing site in Virginia, specializing in active pharmaceutical ingredients (API) and drug product for cancer, autoimmune diseases, and advanced therapies [1] - The new factory will enable Eli Lilly to produce targeted chemotherapies or antibody drug conjugates for the first time [1] - Eli Lilly's goal is to increase manufacturing capacity and bring more manufacturing work in-house [2] - Since 2020, Eli Lilly's total manufacturing investments amount to $50 billion, including a previously announced $27 billion investment in four new sites [4] Tax & Economic Factors - Lower US corporate tax rates (21%) influenced Eli Lilly's decision to build the API site in the US [2][3] - Previously, a 35% corporate tax rate made locating API facilities outside the US more financially attractive [3] Supply Chain & Tariffs - Eli Lilly aims to build a balanced and redundant supply chain to ensure medicine availability for patients [5] - The company is monitoring tariff developments but believes they will not significantly alter its overall strategy [5][6]

Core Insights - EUROAPI released its 2025 condensed Half-Year Consolidated Financial Statements for the six months ending June 30, 2025, available on its website [1][2] - The company focuses on reinventing active ingredient solutions to meet global customer and patient needs, with a portfolio of approximately 200 products [3] - EUROAPI operates five manufacturing sites in Europe and supplies customers in over 80 countries, emphasizing high-quality API manufacturing [4] Financial Overview - The report includes the 2025 half-year management report and the consolidated financial statements as of June 30, 2025 [2] - The Statutory Auditors' review report on the half-yearly financial information is also part of the documentation [2] Company Profile - EUROAPI is a leading player in active pharmaceutical ingredients, developing innovative molecules through its Contract Development and Manufacturing Organization (CDMO) activities [3] - The company employs approximately 3,270 individuals dedicated to enabling access to essential therapies [4] - EUROAPI is listed on Euronext Paris under the ticker EAPI [4]

Group 1 - Euroapi S.A. announced financing from the European Commission and a plan to reorganize its business structure to enhance efficiency in the active pharmaceutical ingredient market [1] - The company operates in a growing sector, indicating potential for future growth and investment opportunities [1] - The analyst has a beneficial long position in the shares of Euroapi S.A., reflecting confidence in the company's prospects [2] Group 2 - The article emphasizes the importance of understanding business models before investing, highlighting a cautious approach to investment [1] - The analyst's experience spans various financial sectors, which may provide valuable insights into the company's performance and market trends [1]

Core Points - The Combined General Shareholders' Meeting of EUROAPI was held on May 21, 2025, in Paris, where all resolutions proposed by the Board of Directors were approved by shareholders [1][2] - The meeting included the approval of the unconsolidated and consolidated financial statements for the year 2024, compensation arrangements for corporate officers, and financial authorizations [2] - EUROAPI's Board of Directors now consists of ten members, with a majority being independent directors, including five independent members and two employee representatives [2] Company Overview - EUROAPI focuses on reinventing active ingredient solutions to meet global customer and patient needs, being a leading player in active pharmaceutical ingredients with around 200 products in its portfolio [3][4] - The company operates six manufacturing sites in Europe and employs approximately 3,430 people, ensuring high-quality API manufacturing for customers in over 80 countries [4] - EUROAPI is listed on Euronext Paris under the ticker EAPI and has strong research and development capabilities [4]

Company Information - EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers' and patients' needs globally, being a leading player in active pharmaceutical ingredients with approximately 200 products in its portfolio [5] - The company has strong research and development capabilities and operates six manufacturing sites located in Europe, ensuring high-quality API manufacturing to supply customers in over 80 countries [6] - EUROAPI is listed on Euronext Paris with ISIN: FR0014008VX5 and ticker: EAPI [6] General Meeting Details - Shareholders are invited to the Combined General Meeting on May 21, 2025, at 10:30 a.m. (CET) in Paris [1] - The notice of the meeting was published in the French official legal announcement publication on April 16, 2025, and in Actu-juridique.fr on April 28, 2025 [1] - Documents related to the General Meeting are available on the company's website under the "Annual General Meeting 2025" section [2] Shareholder Communication - Registered shareholders can request additional documents via email or at the company's registered office, with documentation sent by post or email depending on their preference [3] - Shareholders are encouraged to regularly check the company's website for the latest information regarding the Annual General Meeting, which will be broadcast live unless technical issues arise [4]